TY - JOUR
T1 - Stereotactic body radiotherapy for early glottic cancers
T2 - Is this “The Way”?
AU - Le Guévelou, Jennifer
AU - Larnaudie, Audrey
AU - Blanchard, Pierre
AU - Pointreau, Yoann
AU - Castelli, Joël
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025/7/1
Y1 - 2025/7/1
N2 - In the past decades, several options have been designed in order to preserve vocal function in patients with early glottic cancer, such as transoral laser microsurgery, new surgical strategies such as partial laryngectomy and radiation therapy (RT). With the development of new radiation techniques enabling a more accurate delivery of radiation dose, and the possibility to deliver high dose per fraction while sparing adjacent organs-at-risks (OARs), stereotactic body radiotherapy (SBRT) is being increasingly tested in this disease setting. We aimed to shed light on this appealing strategy, as well as to underline both optimal target population and specific technical considerations.
AB - In the past decades, several options have been designed in order to preserve vocal function in patients with early glottic cancer, such as transoral laser microsurgery, new surgical strategies such as partial laryngectomy and radiation therapy (RT). With the development of new radiation techniques enabling a more accurate delivery of radiation dose, and the possibility to deliver high dose per fraction while sparing adjacent organs-at-risks (OARs), stereotactic body radiotherapy (SBRT) is being increasingly tested in this disease setting. We aimed to shed light on this appealing strategy, as well as to underline both optimal target population and specific technical considerations.
KW - Early glottic cancer
KW - Stereotactic body radiotherapy
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=105002632460&partnerID=8YFLogxK
U2 - 10.1016/j.ctro.2025.100962
DO - 10.1016/j.ctro.2025.100962
M3 - Review article
AN - SCOPUS:105002632460
SN - 2405-6308
VL - 53
JO - Clinical and Translational Radiation Oncology
JF - Clinical and Translational Radiation Oncology
M1 - 100962
ER -